Actinium Pharmaceuticals Names Matt David CFO
(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM), a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer, said Thursday it has appointed Matt David as chief financial officer.
David brings more than 20 years of experience in biopharmaceutical leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc. (CRMD), where he most recently served as executive vice president and chief business officer.
Actinium shares were up about 2% in pre-market trading after closing at $0.9746 on Wednesday.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.